[go: up one dir, main page]

WO2010042475A1 - Analogues de spiroaminooxazoline en tant que modulateurs de récepteur adrénergique alpha2c - Google Patents

Analogues de spiroaminooxazoline en tant que modulateurs de récepteur adrénergique alpha2c Download PDF

Info

Publication number
WO2010042475A1
WO2010042475A1 PCT/US2009/059638 US2009059638W WO2010042475A1 WO 2010042475 A1 WO2010042475 A1 WO 2010042475A1 US 2009059638 W US2009059638 W US 2009059638W WO 2010042475 A1 WO2010042475 A1 WO 2010042475A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
optionally substituted
halo
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/059638
Other languages
English (en)
Inventor
Kevin D. Mccormick
Li Dong
Christopher W Boyce
Manuel De Lera Ruiz
Junying Zheng
Walter S. Won
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of WO2010042475A1 publication Critical patent/WO2010042475A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Definitions

  • the present invention relates to spiroaminooxazoline analogues useful as alpha-2C (or " ⁇ 2C") adrenergic receptor modulators, methods for making these compounds, pharmaceutical compositions containing the compounds, and methods of treatment and prevention using the compounds and compositions to treat disease states associated with the modulation of the alpha-2C receptor, such as congestion (including nasal), migraine, congestive heart failure, cardiac ischemia, glaucoma, stress-induced urinary incontinence, Alzheimer's disesase, Parkinson's disease, attention deficit hyperactivity disorder, pain and psychotic disorders (e.g., depression and schizophrenia).
  • congestion including nasal
  • migraine congestive heart failure
  • cardiac ischemia ischemia
  • glaucoma stress-induced urinary incontinence
  • Alzheimer's disesase Parkinson's disease
  • attention deficit hyperactivity disorder e.g., depression and schizophrenia.
  • ⁇ -adrenergic receptors were shown to be associated with most of the excitatory functions (vasoconstriction, stimulation of the uterus and pupil dilation), ⁇ -adrenergic receptors were implicated in vasodilation, bronchodilation and myocardial stimulation (Lands et al., "Differentiation of Receptor Systems Activated by Sympathomimetic amines," Nature 214:597-598 (1967)). Since this early work, ⁇ -adrenergic receptors have been subdivided into ⁇ 1 - and ⁇ 2-adrenergic receptors.
  • ⁇ -adrenergic receptors Cloning and expression of ⁇ -adrenergic receptors have confirmed the presence of multiple subtypes of both ⁇ 1 -( ⁇ 1 A, ⁇ 1 B, ⁇ 1 D) and ⁇ 2- ( ⁇ 2A, ⁇ 2B, ⁇ 2C) adrenergic receptors (Michel et al., "Classification of ⁇ i - Adrenoceptor Subtypes," Naunyn-Schmiedeberg's Arch. Pharmacol, 352:1-10 (1995); Macdonald et al., "Gene Targeting-Homing in on ⁇ 2 -Adrenoceptor-Subtype Function," TIPS, 18:211-219 (1997)).
  • SLIBSTITUTE SHEET (RULE 26)
  • Current therapeutic uses of ⁇ -2 adrenergic receptor drugs involve the ability of those drugs to mediate many of the physiological actions of the endogenous catecholamines. There are many drugs that act on these receptors to control hypertension, intraocular pressure, eye reddening and nasal congestion and induce analgesia and anesthesia.
  • ⁇ 2 adrenergic receptors can be found in the rostral ventrolateral medulla, and are known to respond to the neurotransmitter norepinephrine and the antihypertensive drug clonidine to decrease sympathetic outflow and reduce arterial blood pressure (Bousquet et al., "Role of the Ventral Surface of the Brain Stem in the Hypothesive Action of Clonidine, " Eur. J. Pharmacol., 34:151-156 (1975); Bousquet et al.,
  • Imidazoline Receptors From Basic Concepts to Recent Developments," 26:S1-S6 (1995)). Clonidine and other imidazolines also bind to imidazoline receptors (formerly called imidazoline-guanidinium receptive sites or IGRS) (Bousquet et al., "Imidazoline Receptors: From Basic Concepts to Recent Developments," 26:S1-S6 (1995)).
  • imidazoline receptors Bostoid et al., "Imidazoline Receptors: From Basic Concepts to Recent Developments," 26:S1-S6 (1995); Reis et al., "The Imidazoline Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine," Ann. N.Y. Acad. ScL, 763:1-703 (1995).
  • Compounds having adrenergic activity are well-known in the art and are described in numerous patents and scientific publications.
  • compositions having an adrenergic compound or compounds as the active ingredient are useful for treating, among other things, glaucoma, chronic pain, migraines, heart failure, and psychotic disorders (e.g., schizophrenia).
  • R 1 -R 3 represent hydrogen, halogen hydroxy, alkyl or alkoxy, and R 5 is hydrogen or alkyl.
  • Another class of compounds reported to have affinity for ⁇ 2 receptors includes the following two compounds (Bagley et.al., Med. Chem. Res. 1994, 4:346-364):
  • ⁇ 2A agonists may be associated with undesirable side effects.
  • side effects include hyper-and hypotension, sedation, locomotor activity, psychotic disorders (e.g., schizophrenia).
  • Another class of compounds reported to have affinity for ⁇ 2 receptors includes the following two compounds (Miller et.al., J. Med. Chem. 1994, 37:2328-2333; J. Med. Chem. 1996, 39:3001-3013; J. Med. Chem. 1997, 37:3014-3024):
  • indane and tetrahyrdonaphthalene type compounds having ⁇ 2- agonist properties is disclosed in PCT application WO 97/12874 and WO20040506356.
  • This class specifically includes MPV-2426 (fadolmidine) and its prodrug esters: wherein R is optionally substituted lower alkyl, aryl, cycloalkyl, heteroaryl, lower alkylamino, and saturated 5- or 6-membered heterocyclic groups containing 1 or 2 N atoms.
  • R is optionally substituted lower alkyl, aryl, cycloalkyl, heteroaryl, lower alkylamino, and saturated 5- or 6-membered heterocyclic groups containing 1 or 2 N atoms.
  • alpha-2C recptor antagonists also describes quinoline derivatives that are alpha-2C recptor antagonists and indicates that these compounds are useful for the treatment of conditions of the pheripheric or CNS system, including treating depression, anxiety, post traumatic stress disorder, schizophrenia, Parkinson's disease and other movement disorders, and dementias (e.g., Alzheimer's disease).
  • WO 2003/082825 also to Orion Corp., indicates alpha-2C receptor antagonists have utility in treating symptoms of disorders and conditions with sensorimotor-gating deficits.
  • ⁇ 2A agonists may be associated with undesirable side effects.
  • side effects include hyper-and hypotension, sedation, locomotor activity, and body temperature variations.
  • X includes -(CH 2 ) 2 -, -O-, -0-CH 2 -, and -S-CH 2 -; of Y includes - O-, -S-, and -N(R 6 )-; and of R 5 includes hydrogen or an amino group.
  • Cordi et al. also disclose spiro[1, 3-diazacyclopent-1-ene)5,2'-(1', 2', 3',4'-tetrahydronaphthylene)] or spiro-imidazolines compounds such as
  • the present invention provides a novel class of heterocyclic compounds that are modulators of the ⁇ 2C adrenergic receptor, or metabolites, stereoisomers, salts, solvates or polymorphs thereof, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more conditions associated with ⁇ 2C receptors using such compounds or pharmaceutical compositions.
  • the present application discloses a compound, or pharmaceutically acceptable salts or metabolites, solvates, prodrugs or polymorphs of said compound, said compound having the general structure shown in Formula I
  • J 1 , J 2 , J 3 and J 4 are independently -N-, -N(O)-, or -C(R 2 )-;
  • X is -C(R 6 XR 6' )-, -N(R 6 )-, -O- or -S -;
  • R c is H or alkyl
  • R 2 is absent or independently selected from the group consisting of H, -OH, halo, -CN, -NO 2 , -S(O) P R 7 , -NR 7 R 7' , and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkoxy, aryloxy, arylalkyl, heteroarylalkyl, and heterocyclylalkyl groups optionally substituted with at least one (preferably 1 to 5, more preferably 1 to 3) R 5 ;
  • R 4 is independently selected from the group consisting of H, D, -OH, halo, -CN, -S(O) p R 7 , -NR 7 R 7' and -S(O) P NR 7 R 7' , and alkyl, deuterated alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl groups optionally substituted with at least one (preferably 1 to 5, more preferably 1 to 3) R 5 ;
  • R 6 is selected from the group consisting of H, -OH, halo, -CN, -NO 2 , -S(O) P R 7 , - NR 7 R 7- , -S(O)pNR 7 R 7' , -C(O)-R 10 , -C(O)-OR 10 , and -C(O)-N(R 7 )R 10 and alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl groups, each of which is optionally substituted with at least one (preferably 1 to 5, more preferably 1 to 3) of halo, -OH, - CN, -NO 2 , -NR 7 R 7' , and -S(O) P R 7 substituents and/or
  • R 7 is independently selected from the group consisting of H and alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloclenyl, cyclocyclenylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, hetrocyclenyl, hetrocyclenylalkyl, heteroaryl, and heteroarylalkyl groups, each of which is optionally substituted one or more times (preferably 1 to 5, more preferably 1 to 3) by R 12 ;
  • R 7 is independently selected from the group consisting of H and alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloclenyl, cyclocyclenylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylal
  • OR 10 , and -S(O) P -OR 10 and alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl groups, each of which is optionally substituted with at least one (preferably 1 to 5, more preferably 1 to 3) of halo, -OH, -CN, -NO 2 , -N(R 11 ) 2 , and -S(O) p R 11 substituents and/or 1 or 2 ( 0);
  • R 11' is independently selected from the group consisting of H, alkyl, alkoxy, alkenyl, alkenyloxy, alkynyl, cycloalkyl, cycloalkoxy, aryl, aryloxy, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl;
  • the compounds of Formula I can be useful as ⁇ 2C adrenergic receptor modulators and can be useful in the treatment or prevention of one or more conditions associated with the ⁇ 2C receptor by administering at least one compound of Formula I to a mammal in need of such treatment.
  • Conditions that my be treated by modulating the ⁇ 2C receptor include allergic rhinitis, congestion (including congestion associated with perennial allergic rhinitis, seasonal allergic rhinitis, non-allergic rhinitis, vasomotor rhinitis, rhinitis medicamentosa, sinusitis, acute rhinosinusitis, or chronic rhinosinusitis, congestion caused by polyps, or caused by the common cold), pain (e.g., neuropathy, inflammation, arthritis, or diabetes), diarrhea, glaucoma, congestive heart failure, chronic heart failure, cardiac ischemia, manic disorders, depression, anxiety, migraine, stress-induced urinary incontinence, neuronal damage from ischemia, schizophrenia, attention deficit hyperactivity disorder, symptoms of diabetes, post traumatic stress disorder, Parkinson's disease or a dementia (e.g., Alzheimer's disease).
  • congestion including congestion associated with perennial allergic rhinitis, seasonal allergic rhinitis, non-allergic rhinitis, vasomotor r
  • Another embodiment of this invention is the treatment or prevention of one or more conditions associated with the ⁇ 2C receptor by administering at least one compound of Formula I to a mammal in need of such treatment by selectively modulating ⁇ 2C adrenergic receptors in the mammal.
  • Another embodiment of this invention is the treatment or prevention of one or more conditions associated with the ⁇ 2C receptor by administering an effective amount at least one compound of Formula I to a mammal in need of such treatment without modifying blood pressure at the therapeutic dose.
  • Another embodiment of the present invention is a method for selectively modulating ⁇ 2C adrenergic receptors in a cell in a mammal in need thereof, comprising contacting said cell with a therapeutically effective amount of at least one compound of Formula I or a pharmaceutically acceptable salt, ester, prodrug or salt thereof.
  • Another embodiment of the present invention is a method for the treatment of congestion in a mammal in need thereof without modifying the blood pressure at therapeutic doses which comprises administering to the mammal an effective dose of at least one compound having adrenergic activity wherein said compound is a selective agonist of the ⁇ 2C receptor.
  • the present invention discloses certain spiroaminooxazoline derivatives, which are represented by structural Formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as described above.
  • J 1 , J 2 , and J 3 are each -C(R 2 )-. In another embodiment, J 2 , J 3 and J 4 are each -CH-.
  • J 2 and J 3 are -CH- and J 1 is -N-.
  • J 1 and J 3 are -CH- and J 2 is -N-.
  • J 1 , J 2 and J 3 are independently -CR 2 - or -N-.
  • J 1 and J 2 are -CH- and J 3 is -N-. In another embodiment, J 1 and J 2 are -CH- and J 3 is -N-.
  • n 1
  • n is 2.
  • n 0.
  • p is an integer from 0-2.
  • X is -CH 2 -.
  • X is -NH-.
  • X is -O-.
  • X is -S-. In another embodiment, X is -N(R 6 )
  • R 1 is bonded to J 1 ; J 2 , J 3 and J 4 are -CH-; and X is - CH 2 -.
  • R 1 is bonded to J 1 ; J 2 , J 3 and J 4 are -CH-; and X is - NH-.
  • R 1 is bonded to J 1 ; J 2 , J 3 and J 4 are -CH-; and X is -O-.
  • R 1 is bonded to J 1 ; J 2 , J 3 and J 4 are -CH-; and X is -S-.
  • R 1 is bonded to J 4 ; J 1 , J 2 and J 3 are -CH-; and X is - CH 2 -. In another embodiment, R 1 is bonded to J 4 ; J 1 , J 2 and J 3 are -CH-; and X is -
  • R 1 is bonded to J 4 ; J 1 , J 2 and J 3 are -CH-; and X is -O-.
  • R 1 is bonded to J 4 ; J 1 , J 2 and J 3 are -CH-; and X is -S-.
  • R 1 is bonded to J 2 ; J 1 , J 3 and J 4 are -CH-; and X is - CH 2 -.
  • R 1 is bonded to J 2 ; J 1 , J 3 and J 4 are -CH-; and X is - NH-.
  • R 1 is bonded to J 2 ; J 1 , J 3 and J 4 are -CH-; and X is -O-.
  • R 1 is bonded to J 2 ; J 1 , J 3 and J 4 are -CH-; and X is -S-. In another embodiment, R 1 is bonded to J 3 ; J 1 , J 2 and J 4 are -CH-; and X is -
  • R 1 is bonded to J 3 ; J 1 , J 2 and J 4 are -CH-; and X is - NH-.
  • R 1 is bonded to J 3 ; J 1 , J 2 and J 4 are -CH-; and X is -O-. In another embodiment, R 1 is bonded to J 3 ; J 1 , J 2 and J 4 are -CH-; and X is -S-.
  • Z is -NR 7 R 7' , wherein R 7 and R 7 are independently H, alkyl, R 12 -aryl, and R 12 -cycloalkyl.
  • R 4 is H, -OH, halo, -CN, -NO 2 , -NR 7 R 7' , wherein R 7 and R 7 are independently H, alkyl, R 12 -aryl, and R 12 -cycloalkyl, alkyl, or haloalkyl
  • m is 1 and W is -O-.
  • m is 1 and W is -S-.
  • the spiro ring is:
  • the spiro ring is:
  • R 15 is H, optionally substituted alkyl, optionally substituted cycloalkyl (e.g., cyclopropyl, cyclopentyl, or cyclohexyl) or, optionally substituted aryl (e.g., phenyl), wherein the optional substitutednts are halo, hydroxyl, amino, alkyl amino, dialkyl amino, nitro, or cyano.
  • optionally substituted alkyl optionally substituted cycloalkyl (e.g., cyclopropyl, cyclopentyl, or cyclohexyl) or, optionally substituted aryl (e.g., phenyl), wherein the optional substitutednts are halo, hydroxyl, amino, alkyl amino, dialkyl amino, nitro, or cyano.
  • Z is amino, alkyl amino or dialkyl amino.
  • R 15 is H or alkyl.
  • R 1 is -[C(R a )(R b )] q YR 7' , -[C(R a )(R b )] q N(R 7 )YR 7' , and -[
  • R 7 and R 7 are independently R 12 -alkyl (e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)); and R 12 - aryl (e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy).
  • R 12 -alkyl e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)
  • R 12 - aryl e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy.
  • the present invention discloses compounds which are represented by structural formulae U-V or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various definitions are those described above for Formula I:
  • R 7 and R 7 are independently H, R 12 -alkyl (e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)); and R 12 -aryl (e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy);
  • R 12 -alkyl e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)
  • R 12 -aryl e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy
  • X is CH 2 or O
  • R 15 is absent or is H or alkyl (e.g., methyl or ethyl).
  • Vl or a pharmaceutically acceptable salt thereof, wherein the definitions are the same as those for Formula I.
  • Another embodiment of compounds of Formula Vl is those compounds wherein
  • R 1 is -[C(R a )(R b )] q YR r , -[C(R a )(R b )] q N(R 7 )YR 7' , -[C(R a )(R b )] q OYR r and -[ C(R a )(R b )] q CN,
  • R 4 is H, D, alkyl or deuterated alkyl (e.g., -CH 2 D, CHD 2 or CD 3 );
  • R 7 and R 7 are independently H, R 12 -alkyl (e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)); and R 12 -aryl (e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy), or a pharmaceutically acceptable salt thereof.
  • R 12 -alkyl e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)
  • R 12 -aryl e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy
  • R 1 is -[C(R a )(R b )] q YR 7 , -[C(R a )(R b )] q N(R 7 )YR 7' , -[C(R a )(R b )] q OYR 7' and -[ C(R a )(R b )] q CN,
  • R 4 is H, D, alkyl or deuterated alkyl (e.g., -CH 2 D, CHD 2 or CD 3 );
  • R 7 and R 7' are independently H 1 R 12 -alkyl (e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)); and R 12 -aryl (e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy), or a pharmaceutically acceptable salt thereof.
  • R 12 -alkyl e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)
  • R 12 -aryl e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy
  • R 1 is -[C(R a )(R b )] q YR r , -[C(R a )(R b )] q N(R 7 )YR 7' , -[C(R a )(R b )] q OYR 7' and -[ C(R a )(R b )] q CN,
  • R 4 is H, D, alkyl or deuterated alkyl (e.g., -CH 2 D, CHD 2 or CD 3 );
  • R 4' is H, D, alkyl or deuterated aikyl (e.g., -CH 2 D, CHD 2 or CD 3 );
  • R 7 and R 7' are independently H, R 12 -alkyl (e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)); and R 12 -aryl (e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy), or a pharmaceutically acceptable salt thereof.
  • R 12 -alkyl e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)
  • R 12 -aryl e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy
  • R 1 is -[C(R a )(R b )] q YR 7> , -[C(R a )(R b )] q N(R 7 )YR 7' , -[C(R a )(R b )] q OYR 7' and -[ C(R a )(R b )] q CN,
  • R 4 is H, D, alkyl or deuterated alkyl (e.g., -CH 2 D, CHD 2 or CD 3 );
  • R 4' is H, D, alkyl or deuterated alkyl (e.g., -CH 2 D, CHD 2 or CD 3 );
  • R 7 and R 7' are independently H, R 12 -alkyl (e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)); and R 12 -aryl (e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy), or a pharmaceutically acceptable salt thereof.
  • R 12 -alkyl e.g., methyl, ethyl, propyl optionally substituted by halo, cyano, or alkoxy (e.g., methoxy)
  • R 12 -aryl e.g., phenyl optionally substituted by alkyl, haloalkyl, cyano, nitro, amino, alkylamino, dialkylamino, hydroxyl or alkoxy
  • a group of compounds falling within Formula I are those shown below: or a pharmaceutically acceptable salt of each of these compounds.
  • the compound of Formula I or its pharmaceutically accept salt, solvate or ester thereof is present in its isolated and purified form.
  • Alpha-2C receptor agonists can by used in the treatment or prevention of allergic rhinitis, congestion (including, but not limited to nasal congestion), migraine, congestive heart failure, chronic heart failure, cardiac ischemia, glaucoma, stress-induced urinary incontinence, attention deficit hyperactivity disorder, neuronal damage from ischemia and psychotic disorders. Further, alpha-2C receptor agonists can be useful in the treatment of pain (both chronic and acute), such as pain that is caused by inflammation, neuropathy, arthritis (including osteo and rheumatoid arthritis), diabetes (e.g., diabetes mellitus or diabetes insipidus) or pain of an unknown origin.
  • neuropathic pain may include but not limited to; diabetic neuropathy, neuralgia of any etiology (e.g. post-herpetic, trigeminal), chemotherapy- induced neuropathy, HIV, lower back pain of neuropathic origin (e.g. sciatica), traumatic peripheral nerve injury of any etiology, central pain (e.g. post-stroke, thalamic, spinal nerve injury).
  • Other pain that can be treated is nociceptive pain and pain that is visceral in origin or pain that is secondary to inflammation or nerve damage in other diseases or diseases of unknown origin.
  • alpha-2C receptor agonists can be useful in the treatment of symptoms of diabetes. Examples of symptoms of diabetes may include but are not limited to: hyperglycemia, hypertriglyceridemia, increased levels of blood insulin and hyperlipidemia.
  • a compound is defined to be an agonist of the alpha-2c receptor if the compound's efficacy at the ⁇ 2C receptor is > 30% E max (GTP ⁇ S assay).
  • a further embodiment of the present invention are that act selectively, and preferably even specifically, as agonists of the ⁇ 2C or the ⁇ 2B/ ⁇ 2C (hereinafter referred to as ⁇ 2C or ⁇ 2B/2C) receptor subtypes in preference over the ⁇ 2A receptor subtype and that act functionally selectively as agonists of the ⁇ 2C or the ⁇ 2B/2C receptor subtype in preference over the ⁇ 2A receptor subtype possess desirable therapeutic properties associated with adrenergic receptors but without having one or more undesirable side effects such as changes in blood pressure or sedation.
  • a compound is defined to be a specific or at least functionally selective agonist of the ⁇ 2C receptor subtype over the ⁇ 2A receptor subtype if the compound's efficacy at the ⁇ 2C receptor is > 30% E ma ⁇ (GTP ⁇ S assay) and its efficacy at the ⁇ 2A receptor is ⁇ 35% E ma x, (GTP ⁇ S assay).
  • the compound acts as an antagonist of the alpha-2C receptor.
  • Alpha-2C receptor antagonists can be used in the treatment or prevention of disease states such as depression, schizophrenia, post tramautic stress disorder, Parkinson's disease, dementias (e.g., Alzheimer's disease and neuropathic disorders.
  • a compound is defined to be an antagonist of the alpha-2C receptor if the compounds's efficacy at the ⁇ 2C receptor is ⁇ 30% E max (GTPYS assay) and the binding inhibition of at the ⁇ 2C receptor (Kj) is ⁇ 500 nM, preferably ⁇ 200 nM, and most preferably ⁇ 20 nM.
  • the ⁇ 2C receptor subtype antagonists possess desirable therapeutic properties associated with the ⁇ 2C adrenergic receptor but without having one or more undesirable side effects associated with ⁇ 2A agonism.
  • compounds that act as antagonists at the ⁇ 2C receptor subtype preferably do not possess an efficacy at the ⁇ 2A receptor of 35% E max or more (GTPyS assay).
  • the present invention provides for a method for the treatment of congestion in a mammal in need thereof which comprises administering to a mammal an effective dose of at least one compound having adrenergic activity wherein said compound is a functionally selective agonist of the ⁇ 2c receptor or the ⁇ 2C/ ⁇ B adrenergic receptor.
  • a further embodiment of the present invention is a method for the treatment of congestion in a mammal in need thereof which comprises administering to a mammal an effective dose of at least one compound having adrenergic activity wherein said compound is a functionally selective agonist of the ⁇ 2C receptor or the ⁇ 2C/ ⁇ B adrenergic receptor, wherein the selective agonist of the ⁇ 2c receptor or the ⁇ 2C/ ⁇ B adrenergic receptor has an efficacy that is greater than or equal to 35% E max when assayed in the GTPyS assay and its efficacy at the ⁇ 2A receptor is ⁇ 35% E max (GTP ⁇ S assay).
  • ⁇ 2C modulator means that a compound has affinity for (or binds to) the ⁇ 2C receptor which provokes a biological response (i.e., either an agonistic or antagonistic response).
  • alpha-2C receptor agonist or "a2C receptor agonist” is a compound that has affinity for the ⁇ 2C receptor and elicits a biological response that mimics the response observed by the endrogenous ligand (e.g., neurotransmitter) that binds to the same receptor.
  • endrogenous ligand e.g., neurotransmitter
  • alpha-2C receptor antagonist or "a2C receptor antagonist” is a compound that has affinity for the ⁇ 2C receptor and elicits a biological response that blocks or dampens the response observed by the endrogenous ligand (e.g., neurotransmitter) that binds to the same receptor.
  • endrogenous ligand e.g., neurotransmitter
  • Congestion refers to all type of congestion including, but not limited to, congestion associated with perennial allergic rhinitis, seasonal allergic rhinitis, non- allergic rhinitis, vasomotor rhinitis, rhinitis medicamentosa, sinusitis, acute rhinosinusitis, or chronic rhinosinusitis or when the congestion is caused by polyps or is associated with the common cold.
  • Alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
  • substituted alkyl means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , carboxy and -C(O)O-alkyl.
  • suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
  • Deuterated alkyl means an alkyl group wherein at least on of the hydrogens in the aliphatic hydrocarbon group is replaced by a deuterium atom.
  • deuterated alkyl groups include, for example, -CDH 3 , -CD 2 H, -CD 3 , -CH 2 CD 3 etc.
  • Alkenyl means an aliphatic hydrocarbon group containing at least one carbon- carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
  • Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain.
  • “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
  • alkenyl may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl).
  • suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut- 2-enyl, n-pentenyl, octenyl and decenyl.
  • Alkynyl means an aliphatic hydrocarbon group containing at least one carbon- carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
  • Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain.
  • “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
  • Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3- methylbutynyl.
  • substituted alkynyl means that the alkynyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
  • Aryl means an aromatic monocyclic or multicyclic ring system, in which at least one of the multicyclic rings is an aryl ring, comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms.
  • the aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • suitable aryl groups include phenyl and naphthyl.
  • Non-limiting examples of aryl multicyclic ring systems include:
  • Heteroaryl means an aromatic monocyclic or multicyclic ring system, in which at least one of the multicyclic rings is aromatic, comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.
  • Preferred heteroaryls contain about 5 to about 6 ring atoms.
  • the “heteroaryl” can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • the prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom.
  • a nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
  • Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4- thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl,
  • Non-limiting examples of hetreroaryl multicyclic ring systems include:
  • Alkyl or arylalkyl means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • Alkylaryl means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
  • Cycloalkyl means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms.
  • Preferred cycloalkyl rings contain about 5 to about 7 ring atoms.
  • the cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
  • suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • suitable multicyclic cycloalkyls include 1-decalinyl, norbomyl, adamantyl and the like.
  • "Halogen" and “Halo” mean fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine or bromine, and more preferred are fluorine and chlorine.
  • Ring system substituent means a substituent attached to an aromatic or non- aromatic ring system which, for example, replaces an available hydrogen on the ring system.
  • Ring system substituents may be the same or different, each being independently selected from the group consisting of aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, YiY 2 N-, YiY 2 N-alky
  • Heterocyclyl means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
  • Preferred heterocyclyls contain about 5 to about 6 ring atoms.
  • the prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
  • Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(CBz), -N(Tos) group and the like; such protected moieties are also considered part of this invention.
  • the heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S 1 S- dioxide.
  • Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, and the like.
  • Compounds of Formula I and salts, esters, solvates and prodrugs thereof may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
  • Non- limiting examples of tautomeric forms that are part of this invention are as follows:
  • Alkynylalkyl means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl. "Heteroaralkyl” means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
  • Heterocyclylalkyl means a heterocyclyl-alkyl group in which the heterocyclyl and the alkyl are as previously described. Preferred heterocyclylalkyls contain a lower alkyl group.
  • suitable heterocyclylalkyl groups include piperidylmethyl, piperidylethyl, pyrrolidylmethyl, morpholinylpropyl, piperazinylethyl, azindylmethyl, azetidylethyl, oxiranylpropyl and the like.
  • the bond to the parent moiety is through the alkyl group.
  • Heterocyclenyl (or “heterocycloalkeneyl”) means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon- nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
  • Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms.
  • the prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
  • the heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above.
  • the nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • Non-limiting examples of suitable monocyclic azaheterocyclenyl groups include 1 ,2,3,4- tetrahydropyridyl, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1 ,2,3,6- tetrahydropyridyl, 1 ,4,5,6-tetrahydropyrimidyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, 2-oxazolinyl, 2-thiazolinyl, and the like.
  • Non-limiting examples of suitable oxaheterocyclenyl groups include 3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, and the like.
  • Non-limiting example of a suitable multicyclic oxaheterocyclenyl group is 7-oxabicyclo[2.2.1]heptenyl.
  • suitable monocyclic thiaheterocyclenyl rings include dihydrothiophenyl, dihydrothiopyranyl, and the like.
  • Heterocyclenylalkyl means a heterocyclenyl-alkyl group in which the heterocyclenyl and the alkyl are as previously described.
  • Hydroalkyl means a HO-alkyl- group in which alkyl is as previously defined.
  • Preferred hydroxyalkyls contain lower alkyl.
  • suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
  • acyl means an organic acid group in which the -OH of the carboxyl group is replaced by some other substituent. Suitable non-limiting examples include H-C(O)-, alkyl-C(O)- , cycloalkyl-C(O)-, heterocyclyl-C(O)-, and heteroaryl-C(O)- groups in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl.
  • Preferred acyls contain a lower alkyl.
  • suitable acyl groups include formyl, acetyl and propanoyl.
  • Aroyl means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl.
  • suitable groups include benzoyl and 1-naphthoyl.
  • Alkoxy means an alkyl-O- group in which the alkyl group is as previously described.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Aryloxy means an aryl-O- group in which the aryl group is as previously described.
  • suitable aryloxy groups include phenoxy and naphthoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Aralkyloxy or “arylalkyloxy” means an aralkyl-O- group in which the aralkyl group is as previously described.
  • suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Heteroarylalkoxy means a heteroarylalkyl-O-group in which the heteroarylalkyl group is as previously described.
  • Heterocyclylalkoxy means a heterocyclylalkyl-O group in which the hetrocyclylalkyl group is as previously described.
  • Heterocyclenylalkoxy means a heterocyclenylalkyl-0 group in which the heterocyclenylalkyl group is as previously described.
  • Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
  • suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
  • Arylthio means an aryl-S- group in which the aryl group is as previously described.
  • suitable arylthio groups include phenylthio and naphthylthio.
  • the bond to the parent moiety is through the sulfur.
  • Alkylthio means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
  • Alkoxycarbonyl means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
  • Aryloxycarbonyl means an aryl-O-C(O)- group.
  • suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
  • the bond to the parent moiety is through the carbonyl.
  • Alkoxycarbonyl means an aralkyl-O-C(O)- group.
  • a suitable aralkoxycarbonyl group is benzyloxycarbonyl.
  • the bond to the parent moiety is through the carbonyl.
  • Alkylsulfonyl means an alkyl-S(O 2 )- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
  • Arylsulfonyl means an aryl-S(O 2 )- group. The bond to the parent moiety is through the sulfonyl.
  • substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • carbons of Formula I can be replaced with 1-3 silicon atoms, provided all valency requirements are satisfied.
  • optional substituted means optional substitution with the specified groups, radicals or moieties.
  • the straight line as a bond generally indicates a mixture of, or either of, the possible isomers, non-limiting example(s) include, containing (R)- and (S)- stereochemistry.
  • the possible isomers include, containing (R)- and (S)- stereochemistry.
  • a dashed line ( — ) represents an optional bond. Lines drawn into the ring systems, such as, for example:
  • the indicated line (bond) may be attached to any of the substitutable ring atoms, non-limiting examples include carbon, nitrogen and sulfur ring atoms.
  • protecting groups When a functional group in a compound is termed "protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York. When any variable (e.g., aryl, heterocycle, R 2 , etc.) occurs more than one time in any constituent or formula, its definition on each occurrence is independent of its definition at every other occurrence.
  • any variable e.g., aryl, heterocycle, R 2 , etc.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Prodrugs and solvates of the compounds of the invention are also contemplated herein.
  • the term "prodrug”, as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of formula I or a salt and/or solvate thereof.
  • prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) Volume 14 of the A.C.S.
  • a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-C 8 )alkyl, (C 2 - C 12 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1- methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbo ⁇ yloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxy)alkyl, (C 2 - C 12 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (CrC ⁇ alkanoyloxymethyl, 1-((C r C 6 )alkanoyloxy)ethyl, 1-methyl-1-((Ci-C 6 )alkanoyloxy)ethyl, (C 1 - C 6 )alkoxycarbonyloxymethyl, N ⁇ d-C ⁇ jalkoxycarbonylaminomethyl, succinoyl, (d- C 6 )alkanoyl, ⁇ -amino(CrC 4 )alkanyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ - aminoacyl, where each ⁇ -aminoacyl group is independently selected from the naturally occurring L-amino acids, -P(O)(OH) 2 , -P(O)(O
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'- carbonyl where R and R' are each independently (Ci-Cio)alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural ⁇ -aminoacyl or natural ⁇ -aminoacyl, -C(OH)C(O)OY 1 wherein Y 1 is H, (C r C 6 )alkyl or benzyl, -C(OY 2 )Y 3 wherein Y 2 is (C r C 4 ) alkyl and Y 3 is (Ci-C6)alkyl, carboxy (
  • One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of illustrative solvates include ethanolates, methanolates, and the like.
  • “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
  • One or more compounds of the invention may optionally be converted to a solvate.
  • Preparation of solvates is generally known.
  • M. Caira et a/ J. Pharmaceutical ScL, 93(3). 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
  • Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et a/, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et a/, Chem. Commun., 603-604 (2001).
  • a typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
  • Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
  • Metabolic conjugates such as glucuronides and sulfates which can undergo reversible conversion to the compounds of of Formula I are contemplated in the present invention.
  • Effective amount or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
  • purified or “in purified form,” as used herein, for a compound refers to the physical state of said compound after being isolated from a synthetic process (e.g. from a reaction mixture), or natural source or combination thereof.
  • the term “purified”, “in purified form” or “in isolated and purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan (e.g., chromatography, recrystallization and the like) , in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
  • “Capsule” is meant to describe a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients.
  • Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
  • Tablet is meant to describe a compressed or molded solid dosage form containing the active ingredients with suitable diluents.
  • the tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.
  • Oral gels is meant to describe to the active ingredients dispersed or solubilized in a hydrophillic semi-solid matrix.
  • “Powders for constitution” refers to powder blends containing the active ingredients and suitable diluents which can be suspended in water or juices.
  • “Diluent” refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose.
  • the amount of diluent in the composition can range from about 10 to about 90% by weight of the total composition, preferably from about 25 to about 75%, more preferably from about 30 to about 60% by weight, even more preferably from about 12 to about 60%.
  • D is integrants refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments.
  • Suitable disintegrants include starches; "cold water soluble” modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures.
  • the amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to about 10% by weight.
  • Binders refers to substances that bind or "glue” powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose and sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate.
  • sugars such as sucrose
  • starches derived from wheat, corn rice and potato natural gums such as acacia, gelatin and tragacanth
  • derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate
  • the amount of binder in the composition can range from about 2 to about 20% by weight of the composition, more preferably from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.
  • “Lubricant” is meant to describe a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear.
  • Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d'l-leucine.
  • Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press.
  • the amount of lubricant in the composition can range from about 0.2 to about 5% by weight of the composition, preferably from about 0.5 to about 2%, more preferably from about 0.3 to about 1.5% by weight.
  • “Glidents” means materials that prevent caking and improve the flow characteristics of granulations, so that flow is smooth and uniform. Suitable glidents include silicon dioxide and talc. The amount of glident in the composition can range from about 0.1% to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.
  • Coloring agents refers to excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1%.
  • Bioavailability refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.
  • Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures.
  • Conventional methods for making other forms for administration such as, for example, capsules, suppositories and the like are also well known.
  • the compounds of Formula I can form salts which are also within the scope of this invention.
  • Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the term "salt(s)" denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • zwitterions inner salts may be formed and are included within the term "salt(s)" as used herein.
  • Salts of the compounds of Formula I or may be formed, for example, by reacting a compound of Formula I with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tarta rates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons or sulfurs on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention.
  • a compound of Formula I incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
  • the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
  • the use of the terms "salt”, “solvate” "prodrug” and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrugs of the inventive compounds.
  • Diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diasteromeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • some of the compounds of Formula I may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention.
  • Enantiomers can also be separated by use of chiral HPLC column.
  • polymorphic forms of the compounds of Formula I, and of the salts, solvates and prodrugs of the compounds of Formula I 1 are intended to be included in the present invention.
  • the present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 CI, respectively.
  • Certain isotopically-labelled compounds of Formula I are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability.
  • lsotopically labelled compounds of Formula I can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
  • the compounds according to the invention have pharmacological properties; in particular, the compounds of Formula I can be useful as ⁇ 2C adrenoreceptor agonists.
  • a preferred dosage is about 0.001 to 500 mg/kg of body weight/day of the compound of Formula I.
  • An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of a compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound.
  • the compounds of this invention may also be useful in combination (administered together or sequentially) with one or more therapeutic agents such as, for example, glucocorticosteroids, PDE-4 inhibitors, anti-muscarinic agents, cromolyn sodium, Hi receptor antagonists, 5-HT 1 agonists, NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin Il receptor agonists, ⁇ -blockers, ⁇ -agonists (including both long and short acting), leukotriene antagonists, diuretics, aldosterone antagonists, ionotropic agents, natriuretic peptides, pain management/analgesic agents, anti-anxiety agents, anti-migraine agents, and therapeutic agents suitable for treating heart conditions, psychotic disorders, and glaucoma.
  • therapeutic agents such as, for example, glucocorticosteroids, PDE-4 inhibitors, anti-muscarinic agents, cromolyn sodium, Hi receptor antagonists, 5-HT 1 agonists
  • Suitable steroids include prednisolone, fluticasone (including all ester such as the propionate or furoate esters), triamcinolone, beclomethasone, mometasone (including any ester form such as mometasone furoate), budasamine, ciclesonide betamethasone, dexamethasone, prednisone, flunisolide, and cortisone.
  • Suitable PDE-4 inhibitors include roflumilast, theophylline, rolipram, piclamilast, cilomilast and CDP-840.
  • Suitable antiimuscarinic agents include ipratropium bromide and tiatropium bromide.
  • Suitable Hi antagonists include astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratidine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizeine, fexofenadine, hydroxyzine, ketotifen, loratidine, levocabastine, meclizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelen
  • Suitable anti-inflammatory agents include aspirin, diclofenac, diflunisal, etodolac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, and tolmetin.
  • Suitable aldosterone antagonists include spironolactone.
  • Suitable ionotropic agents include digitalis.
  • Suitable angiotensin Il receptor agonists include irbesartan and losartan.
  • Suitable diuretics include spironolactone, methyclothiazide, bumetanide, torsemide, hydroflumethiazide, trichlormethiazide, hydroclorothiazide, triamterene, ethacrynic acid, methyclothiazide, hydrochlorothiazide, benzthiazide, hydrochlorothiazide, quinethazone, hydrochlorothiazide, chlorthalidone, furosemide, indapamide, hydroclorothiazide, triamterene, trichlormethiazide, hydrochlorothiazide, amiloride HCI, amiloride HCI 1 metolazone, trichlormethiazide, bendroflumethiazide, hydrochlorothiazide, polythiazide, hydro
  • Suitable pain management/analgesic agents include Celecoxib, amitriptyline, ibuprofen, naproxen, gabapentin, tramadol, rofecoxib, oxycodone HCI, acetaminophenoxycodone HCI, carbamazepine, amitriptyline, diclofenac, diclofenac, etodolac, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac tromethamine, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin sodium, valdecoxib, diclofenac/ misoprostol, oxycontin, vicodin, darvocet, percocet, morphine sulfate, dilaudid
  • Suitable ⁇ -blockers include acebutolol, atenolol, atenolol/chlorthalidone, betaxolol, bisoprolol fumarate, bisoprolol/HCTZ, labetolol, metoprolol tartrate, nadolol, pindolol, propranolol, propranolol/HCTZ, sotalol, and timolol.
  • Suitable ⁇ -agonists include dobutamine, ritodrine, salbutamol, levalbuterol, metaproternol, formoterol, fenoterol, bambuterol, brocaterol, clenbuterol, terbutaline, tulobuterol, epinephrine, isopre ⁇ alin, and hexoprenalin.
  • Suitable leucotriene antagonists include levamisole.
  • Suitable anti-migraine agents include rovatriptan succinate, naratriptan HCI 1 rizatriptan benzoate, sumatriptan succinate, zolmitriptan, almotriptan malate, methysergide maleate, dihydroergotamine mesylate, ergotamine tartrate, ergotamine tartrate/caffeine, Fioricet ® , Fiorninal ® , Depakene ® , and Depakote ® .
  • Suitable anti-anxiety and anti-depressant agents include amitriptyline HCI, bupropion HCI, citalopram hydrobromide, clomipramine HCI, desipramine, fluoxetine, fluvoxamine maleate, maprotiline HCI, mirtazapine, nefazodone HCI, nortriptyline, paroxetine HCI 1 protriptyline HCI, sertraline HCI, doxepin, and trimipramine maleate.
  • Suitable angiotensin converting enzyme inhibitors include Captopril, enalapril, enalapril/HCTZ , lisinopril, lisinopril/HCTZ, and Aceon ® .
  • compositions which comprise at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18 th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.
  • Liquid form preparations include solutions, suspensions and emulsions.
  • solubility enhancing components are described, for example, in U.S. 6,673,337 in column 2, line 50 to column 3, line 17 and in column 6, line 49 to line 31 ; US 6,673,337 is expressly incorporated by reference.
  • Specific solubility enhancing agents that are excluded in the liquid form preparations include metal carboxymethylcelluloses, metal carboxymethylhydroxyethylcelloses, hydroxypropylmethyl celluloses derivative of these compounds, and cyclodextrins.
  • Liquid form preparations may also include solutions or suspensions for intranasal administration.
  • composition in a solid dosage form comprising a compound of Formula I or a pharmaceutical acceptable salt, ester, solvate or prodrug thereof and a least one pharmaceutically acceptable carrier, adjuvant or vehicle.
  • a liquid, aqueous pharmaceutical composition is comprising a compound of Formula I or a pharmaceutical acceptable salt, ester, solvate or prodrug thereof and a least one pharmaceutically acceptable carrier, adjuvant or vehicle provided that the adjuvant is not a solubility enhancing component, such as those described in US 6,673,337 (discussed above).
  • a liquid, aqueous pharmaceutical composition is comprising a compound of Formula I or a pharmaceutical acceptable salt, ester, solvate or prodrug thereof and a least one pharmaceutically acceptable carrier, adjuvant or vehicle wherein if a solubility enhancement component is present it is cyclodextrin.
  • Another aspect of this invention is a pharmaceutical formulation that is a nasal spray wherein the pH is equal to or less that about 6.5, more preferably between about 6.1 to 6.2.
  • the formulation is a nasal spray wherein the adjuvants include a suspending agent (e.g., AVICEL (such as AVICIL RC-581 , RC- 591 and CL-611), which are microcrystalline cellulose and carboxymethylcellulose sodium; hydroxypropylmethyl cellulose; methyl cellulose; polyvinyl alcohol; or CARBOPOL) and a humectant (e.g., glycerin, propylene glycol; polyethylene glycol; povidone; or dextrose).
  • AVICEL such as AVICIL RC-581 , RC- 591 and CL-611
  • a humectant e.g., glycerin, propylene glycol; polyethylene glycol; povidone; or dextrose
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions or suspensions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
  • the compounds of the invention may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compounds of this invention may also be delivered subcutaneously.
  • the compound is administered orally.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 100 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • the amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
  • a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
  • kits comprising a therapeutically effective amount of at least one compound of Formula I, or a pharmaceutically acceptable salt or solvate of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.
  • kits comprising an amount of at least one compound of Formula I 1 or a pharmaceutically acceptable salt or solvate of said compound and an amount of at least one therapeutic agent listed above, wherein the amounts of the two or more ingredients result in desired therapeutic effect.
  • the compounds in the invention may be produced by a variety of processes know to those skilled in the art and by know processes analogous thereto.
  • the invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art. The practitioner is not limited to these methods.
  • the prepared compounds may be analyzed for their composition and purity as well as characterized by standard analytical techniques such as, for example, elemental analysis, NMR, mass spectroscopy and IR spectra.
  • reagents and solvents actually used may be selected from several reagents and solvents well known in the art to be effective equivalents.
  • solvent or reagent it is meant to be an illustrative example of the conditions desirable for that particular reaction scheme and in the preparations and examples described below.
  • Bn benzyl
  • BINAP 2,2'-bis(diphenylphosphino)-1 ,1'-bisnaphthyl
  • DMAP 4-dimethylaminopyridine
  • DIBAL diisobutylaluminum hydride
  • DIPEA diisopropylethylamine
  • HATU 0-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
  • HOBt 1-hydroxybenzotriazole
  • LAH lithium aluminum hydride
  • NMO N-methylmorpholine N-oxide
  • TBS t-butyldimethyl silyl
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • Tos or Ts p-toluenesulfonyl (tosyl)
  • ToI toluene
  • TosMIC Toluenesulfonylmethyl isocyanide
  • TPAP tetrapropylammonium perruthenate
  • a cyanide source such as KCN , NaCN or TMSCN; or related conditions such as CO 2 /NH 4 OH/NaCN/ H 2 O 2 .
  • Subsequent hydrolysis to the amino acid S3a with base LiOH, NaOH, Ba(OH) 2 , or the like
  • the amino ester S3b is followed by conversion to the amino ester S3b and reduction to the alcohol S4 (with reagents such as as DIBAL, NaBH 4 , borane, or LAH).
  • the amino acid S3a is directly reduced to S4.
  • the amino alcohol (S4) is then cyclized to provide the following moieties:
  • EtOCS 2 H Im 2 CS, CS 2 , CI 2 CS, NaSCH, or MeSC(S)OEt etc.
  • the functionalized A group may exist in the starting material S1 or its precursor.
  • A halogen or alcohol
  • functionalization may occur a metal catalyzed or metal-faciliated process (with copper, palladium, or other metals).
  • the functionalized R 2 and R 3 groups may exist in the starting material S1 or its precursor.
  • S1 or its precursor may be functionalized with R 2 and R 3 groups at various stages in the sequence.
  • compound S1 is converted to S6 by a Strecker reaction (with a cyanide source and an amine such as NhUCI/KCN or alkylamine/NaCN).
  • the nitrile is reduced (with LAH or a similar reagent) to S7, which may be cyclized to provide S8 or S9.
  • compound S6 is converted to amino acid S3a (Scheme 1) by hydrolysis.
  • compound S5d or S5e is converted to S10 (via chlorination with SOCI 2 , POCI 3 , PCI 3 , PCI 5 , Cl 2 or the like).
  • intermediate S10 is displaced with an amine, oxygen or carbon nucleophile or alternatively reacted in a metal catalyzed or metal-facilitated process (such as a palladium-catalyzed Suzuki or Stille coupling) to provide S5 (in which Z is a carbon, oxygen or nitrogen linked substituent).
  • a metal catalyzed or metal-facilitated process such as a palladium-catalyzed Suzuki or Stille coupling
  • Scheme 4 shows an approach in which amino alcohol S4 is reacted with an acid under standard coupling conditions (with reagents such as EDCI, HOBt etc.) or with an acid chloride to provide the amide S11 (wherein R is defined as Z in Formula I or a group that may be converted into Z).
  • compound S11 is then treated with sulfur reagent such as Lawesson's Reagent, P 2 S 5 , or Deoxy-Fluor to affect incorporation of S with concomitant cyclization to S12.
  • S4 may be converted to thioamide or thiourea S13 (by reaction with a thioester, thioacid, or thioisocyanate) and then cyclized to S12 (under a variety of conditions including treatment with HCI, SOCI 2 , Deoxy-Fluor, DAST, Hg(O), Hg(OAc) 2 or 2-chloro-3- ethylbenzoxazolium tetrafluoroborate or other reagents).
  • S11 is first converted to S13 (by treatment with a sulfur reagent such as Lawesson's Reagent , DAST or the like) and then cyclized to S12 in a step-wise fashion.
  • aminoester S3b (optionally protected) is sequentially treated with an organometallic reagent (such as a RMgBr, a Grignard reagent, or RLi, an alkyllithium compound, to give a ketone S15), followed by reduction to afford S17 (wherein R is defined as R 4 in Formula I or a group that may be converted into R 4 ).
  • organometallic reagent such as a RMgBr, a Grignard reagent, or RLi, an alkyllithium compound
  • this general approach may be taken starting with the amino nitrile S6 or Weinreb amide S14 (accessed from aminoacid S3a by amide coupling with HN(Me)OMe or from aminoester S3b reaction with HN(Me)OMe/AIMe 3 ).
  • S3b, S6, or S14 are reduced (or reduced/oxidized) to aldehyde S16 which is then subsequentially reacted with an organometallic reagent to provide S17.
  • the reduction of ketone S15 may optionally be undertaken in a stereoselective manner to preferentially provide one stereoisomeric alcohol S17.
  • Reagents for a stereoselective reduction include, but are not limited to the CBS- oxazaborolidine/borane reagent, LAH/N-methylephedrine, BINAL-H, IpC 2 BCI, DIBAL- H, Li-selectride, NaBH_(/CeCl3, and enzymatic catalysis.
  • ketone S15 (optionally protected) undergoes an olefination (Wittig, Horner-Emmons, Tebbe reaction etc.) hydroboration sequence to provide alcohol S20 (wherein R is defined as R 4 in Formula I or a group that may be converted into R 4 ), which is then cyclized to S21.
  • ketone S15 (optionally protected) undergoes an olefination (Wittig, Horner-Emmons etc.) to a 1 ,2- disubstituted olefin.
  • Hydroboration of S22 (wherein R and R' are independently defined as R 4 in Formula I or a group that may be converted into R 4 ) provides alcohol S23, which is then cyclized to S24.
  • alcohol S20 (optionally protected) is sequentially oxidized and treated with an organometallic reagent to provide S23 (wherein R and R' are independently defined as R 4 in Formula I or a group that may be converted into R 4 ). Compound S23 is then cyclized to provide S24.
  • chiral alcohol S28 is prepared by the addition of the anion of a chiral sulfoxide S27 onto ketone S26.
  • An intramolecular SN2 reaction provides epoxides S29, which are opened using nitrogen nucleophiles such as ammonia or by addition of NH ⁇ precursors such as azides, phthalimides, benzyl amines or benzhydryl amines to give aldehyde S30.
  • Alcohols S31 and S32 are prepared by addition of an organometallic compound (such as an organomagnesium) and amine deprotection.
  • chiral sulfoxide S33 contains an alkyl group R'.
  • epoxide opening provides ketone S36.
  • Alcohols S31 and S32 are obtained by reduction of the ketone by known methods (such as treatement with as NaBH 4 ) and amine deprotection.
  • the ketone is reduced in an asymmetrical fashion using chiral reduction methods known for those skilled in the art (such as CBS reduction).
  • compound S1 is treated with a chiral amine (such as ( " Rj-phenylglycine or other chiral amine) and then treated with a cyanide source (such of KCN, NaCN or TMSCN) to provide converted to S6 as a pure enantiomer or in enantiomerically enriched form.
  • a chiral amine such as ( " Rj-phenylglycine or other chiral amine
  • a cyanide source such of KCN, NaCN or TMSCN
  • the ester S3b is converted to amide S3c (by treatment with ammonia or an amine) and then reduced (with LAH, BH3 or a similar reagent) to diamine S38, which may be cyclized to provide: -S39a, via treatment with amidine reagents such as formamidine, acetamidine, or benzamidine);
  • -S39b via treatment with diphenyl cyanocarbonimidate
  • -S39c via treatment with cyanogen bromide
  • -S39d via treatment with carbonyldiimidazole, triphosgene, or related carbonates or chloroformates etc.
  • a N- protected glycine ester such as N-(diphenylmethylene)glycine ethyl ester or N- benzylideneglycine ethyl ester
  • Use of chiral N-protectected glycine ester or use of a chiral phase-transfer catalyst with a nonchiral N-protected glycine ester provides enantioselective enhancement in the condensation.
  • S40b is condensed with a malo ⁇ ate ester (such as dimethyl malonate) to provide S43.
  • a malo ⁇ ate ester such as dimethyl malonate
  • Selective enzymatic hydrolysis of one ester provides S44 which is converted to S45 by a Curtuis rearrangement and then further elaborated to S42.
  • the starting materials, including compound S1, S26, and S40, and reagents used in preparing compounds described are either available from commercial suppliers such as Aldrich Chemical Co. (Wisconsin, USA) and Acros Organics Co. (New Jersey, USA) or were prepared by literature methods known to those skilled in the art.
  • compound S1 (optionally substituted with R 2 and R 3 , or with substituents that are converted into R 2 and R 3 ) is synthesized from S46, S47, S48, S49, or other starting materials according to methods known in the literature.
  • Steps 2-3 A mixture of 1A (4.46 g, 15.1 mmol) and LiOH-H 2 O (3.18g, 75.6 mmol) in H 2 O
  • 6-bromo-3-chromanone 3B was prepared from 6- bromo-4-chromanone in a 4 step sequence as outlined in Synthesis, 1980, 621: reduction with NaBH 4 (1.2 eq, MeOH-DCM, O 0 C to RT, 2h), elimination with pTsOH (cat., toluene, reflux, 3h, 90% for 2-steps), osmylation (cat. OsO 4 , 1 eq. NMO, water-acetone-tBuOH, RT, overnight) and final treatment with pTsOH (cat., toluene, reflux, 15min, 86% for 2-steps).
  • Compound ( ⁇ )-3 is prepared compound from 3B following essentially the same procedures as described in Example 1.
  • compound ( ⁇ )-3 is prepared from 6-nitro-3-chromanone (prepared from 6-nitro-4-chromanone) in a manner similar to that described in Example 4.
  • 5A 5B A suspension of 5A (200 mg, 0.813 mmol) and Ba(OH) 2 (460 mg, 3.25 mmol) in water (2 mL) was heated in a sealed tube at 120 0 C for 36 h. The mixture was acidified with 6 N H 2 SO 4 , and filtered and the filter pad was washed with MeOH repeatedly. The combined filtrate was concentrated under reduced pressure to yield the amino acid as an off-white solid. The crude product was added to a mixture of SOCI 2 (145 mg, 1.219 mmol) and MeOH (10 mL). The mixture was stirred at reflux for 3 h, cooled to RT and concentrated under reduced pressure.
  • ( ⁇ )-12 is protected (e.g. with CBzCI), reacted in the coupling reactions described above and then deprotected (e.g. Pd-C, H 2 ) to provide the final compounds.
  • deprotected e.g. Pd-C, H 2
  • Compound ( ⁇ )-14 was prepared from 7-bromo-2-tetralone in a manner similar to that described in Example 1 : hydantoin formation with (NhU) 2 CCVKCN, hydrolysis with LiOH, methyl ester formation with SOCI 2 /Me0H, reduction with NaBH 4 , cyclization with benzoyl isothiocyanate, and hydrolysis with LiOH to provide ( ⁇ )-14 (LCMS m/z 281/283, MH+).
  • KOtBu 39 mg, 0.35 mmol was added to a solution of a mixture of diastereomeric alcohols 15B (120 mg, 0.29 mmol) in a 1:1 mixture of dry tBuOH and dry THF (20 mL) at RT. The resulting mixture was stirred for 1.5 h and KOtBu (13 mg, 0.12 mmol) was added. The mixture was stirred for another 30 min and the solvent evaporated. Water was added and the mixture was extracted with DCM.
  • compound ( ⁇ )-16B is then subjected to coupling with Cul/EtNH 2 , reaction with CICO 2 Me, and deprotection with LiOH to provide the title compound ( ⁇ )-16.
  • Compound 5A was brominated (as described in Example 16) to provide 17A, which was further advanced to compound 17C in a manner similar to that previously described.
  • 8-Bromochroman-3-one 23B was prepared from 2-bromophenol in a manner similar to that described in the literature (J. Med. Chem., 1988, 689):
  • Compound 23D was prepared from 23B in a manner similar to that described in Example 1 : hydantoin formation with (NH 4 J 2 CO 3 ZKCN, hydrolysis with LiOH, methyl ester formation with SOC ⁇ /MeOH, and reduction with NaBH 4 .
  • the reaction of compound 23D with cyanogen bromide provided 23E (THF, RT, 3h).
  • compound 28G was subjected to the following sequence: hydantoin formation with (NH 4 ) 2 C ⁇ 3/KCN, hydrolysis with LiOH, methyl ester formation with SOCI 2 /MeOH, reduction with NaBH 4 , and cyclization with BrCN to provide ( ⁇ )-28H (LCMS m/z 295/297, MH+).
  • compound 29B was synthesized from 18A by the following two- step procedure:
  • reaction of 18A with ethylamine followed by reduction with BH 3 -SMe 2 provided 33E, which was cyclized with formamidine acetate to provide ( ⁇ )-33F and acetamidine hydrochloride to provide ( ⁇ )-33G (LCMS m/z 307/309, MH+), respectively.
  • compound ( ⁇ )-33F is converted to ( ⁇ )-33H.
  • compound ( ⁇ )-33G is converted to ( ⁇ )-33l.
  • 34G (0.113 mol) was dissolved in benzene (360 mL). The flask was cooled to 0 0 C in an ice/water bath and anhydrous zinc diiodide (43.4g, 0.136 mol) was gradually added. The resulting mixture was stirred at 0 °C for 10 min before it was warmed to RT and stirred for 4 h. The mixture washed with water in two portions followed by a final wash with brine. The organic phase was dried over anhydrous sodium sulfate and concentrated to dryness to provide 34B (99%).
  • Another alternative preparation of 34E is described below:
  • the benzophenone byproduct was removed from reaction mixture by extracting with diethyl ether.
  • the product was isolated by cooling the aqueous layer in an ice bath, neutralizing with 1 N NaOH, and extracting with diethyl ether.
  • the ether extract was concentrated to provide 34I.
  • Steps 3-4 A solution of 35A (430 mg, 1.21 mmol) in THF (15 mL) was cooled to -78 0 C and treated with MeMgBr (3.0 N/THF, 0.93 mL, 2.3 eq) dropwise. The mixture was allowed to warm to RT slowly and then was quenched with sat. aq. NH 4 CI at 0 0 C. The reaction was extracted with DCM. The combined organic extracts were dried over Na 2 SO 4 , concentrated and purified to provide a mixture of 35B (minor product) and 35C (major product).
  • compound 35A was converted directly to compound 35B by use of DCM as solvent: A mixture of 35A (3.49g, 9.8 mmol) in DCM (50 mL) was cooled to -78 0 C and treated with MeMgBr (3.0 N/THF, 8.2 ml_, 2.5 eq) dropwise. The mixture was allowed to warm to RT, stirred 1h, and then was quenched with sat. aq. NH 4 CI at 0 0 C. The reaction was extracted with DCM. The organic layer was dried over Na 2 SO 4 , concentrated and purified to provide 35B (3.61 g) as a white foam.
  • DCM DCM as solvent
  • compound 34E was sequentially protected with BoC 2 O, oxidized with TPAP/NMO or Dess-Martin reagent, and treated with MeMgBr (in DCM, -78 0 C to RT overnight or in THF, 1h, -78 0 C ) to provide 36C.
  • 36C was deprotected with TFA, cyclized with EtOC(O)NCS/Hg(OAc) 2 , and hydrolyzed with LiOH to provide ( ⁇ )-36E.
  • compound 36B is treated with CD 3 MgBr (prepared from CD 3 Br, see J. Am. Chem. Soc. 1989, 111 , 3897) and then advanced to ( ⁇ )-40B.
  • CD 3 MgBr prepared from CD 3 Br, see J. Am. Chem. Soc. 1989, 111 , 3897
  • 42C is reduced in a steroselective manner with (S)-2-methyl-CBS-oxazaborolidine/borane or (R)-2-methyl-CBS-oxazaborolidine/borane as described in Example 66.
  • Step i A mixture of 3-bromo-6-fluoro-o-xyle ⁇ e (25.37g, 432 mmol) in anhydrous CCI 4
  • Efficacy agonist activity values for ⁇ 2A and ⁇ 2C were determined by following the general procedure detailed by Umland et. a/ ("Receptor reserve analysis of the human ⁇ 2C -adrenoceptor using [ 35 S]GTPyS and cAMP functional assays" European Journal of Pharmacology 2001, 411, 211-221).
  • a compound is defined to be active agonist of the ⁇ 2C receptor subtype if the compound's efficacy at the ⁇ 2C receptor is ⁇ 30% Emax (GTP ⁇ S assay).
  • a compound is defined to be a specific or at least functionally selective agonist of the ⁇ 2C receptor subtype if the compound's efficacy at the ⁇ 2C receptor is ⁇ 30% Emax (GTP ⁇ S assay) and its efficacy at the ⁇ 2A receptor is ⁇ 35% Emax (GTP ⁇ S assay).
  • a compound is defined to be an antagonist of the ⁇ 2C receptor subtype if the compound's efficacy at the ⁇ 2C receptor is ⁇ 30% Emax (GTP ⁇ S assay) and the Kj at the ⁇ 2C receptor subtype is ⁇ 500 nM, preferentially ⁇ 200 nM, and most preferentially ⁇ 20 nM.
  • the following compounds were evaluated to be active or functionally selective agonists of the ⁇ 2C receptor subtype based on the previously defined definition: ( ⁇ )- 8, ( ⁇ )-10, ( ⁇ )-10B, ( ⁇ )-11, ( ⁇ )-11B and ( ⁇ )-12c.
  • the following compound was evaluated to be an antagonist of the ⁇ 2C receptor subtype based on the previously defined definition (K 1 ⁇ 200 nM): ( ⁇ )-5, and ( ⁇ )-9.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne, dans ses nombreux modes de réalisation, une nouvelle classe d’analogues de spiroaminooxazoline en tant que modulateurs de récepteur adrénergique α2C, des procédés de préparation de tels composés, des compositions pharmaceutiques contenant un ou plusieurs de ces composés, des procédés de préparation de formulations pharmaceutiques comprenant un ou plusieurs de ces composés, et des procédés de traitement, prévention, inhibition ou amélioration d’une ou plusieurs affections associées aux récepteurs adrénergiques α2C utilisant de tels composés ou compositions pharmaceutiques.
PCT/US2009/059638 2008-10-07 2009-10-06 Analogues de spiroaminooxazoline en tant que modulateurs de récepteur adrénergique alpha2c Ceased WO2010042475A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10338508P 2008-10-07 2008-10-07
US61/103,385 2008-10-07

Publications (1)

Publication Number Publication Date
WO2010042475A1 true WO2010042475A1 (fr) 2010-04-15

Family

ID=41397553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059638 Ceased WO2010042475A1 (fr) 2008-10-07 2009-10-06 Analogues de spiroaminooxazoline en tant que modulateurs de récepteur adrénergique alpha2c

Country Status (3)

Country Link
AR (1) AR073630A1 (fr)
TW (1) TW201026672A (fr)
WO (1) WO2010042475A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057973A1 (fr) * 2009-11-11 2011-05-19 F. Hoffmann-La Roche Ag Dérivés d'oxazoline pour le traitement de troubles du système nerveux central (cns)
WO2012168162A1 (fr) 2011-06-06 2012-12-13 F. Hoffmann-La Roche Ag Acide acétique de benzocylcoheptène
US9630922B2 (en) 2015-04-17 2017-04-25 Forma Therapeutics, Inc. 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
US10112915B2 (en) 2015-02-02 2018-10-30 Forma Therapeutics, Inc. 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10961221B2 (en) 2013-12-19 2021-03-30 Bayer Pharma Aktiengesellschaft Substituted piperidinyl tetrahydroquinolines

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635495A2 (fr) * 1993-07-20 1995-01-25 Adir Et Compagnie Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2004082602A2 (fr) * 2003-03-14 2004-09-30 Merck & Co. Inc. Antagonistes des recepteurs du cgrp a base de carboxamide spirohydantoine
WO2004087649A2 (fr) * 2003-03-14 2004-10-14 Merck & Co., Inc. Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
WO2006031676A2 (fr) * 2004-09-13 2006-03-23 Merck & Co., Inc. Antagoniste des recepteurs cgrp spirohydantoin anilide tricyclique
WO2007016087A2 (fr) * 2005-07-29 2007-02-08 Merck & Co., Inc. Antagonistes des récepteurs de cgrp de benzodiazépine hétérocyclique
WO2008073251A1 (fr) * 2006-12-08 2008-06-19 Merck & Co., Inc. Composés spirocycliques contraints servant d'antagonistes des récepteurs du cgrp
WO2008100456A2 (fr) * 2007-02-13 2008-08-21 Schering Corporation Agonistes des récepteurs adrénergiques alpha2c fonctionnellement sélectifs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635495A2 (fr) * 1993-07-20 1995-01-25 Adir Et Compagnie Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2004082602A2 (fr) * 2003-03-14 2004-09-30 Merck & Co. Inc. Antagonistes des recepteurs du cgrp a base de carboxamide spirohydantoine
WO2004087649A2 (fr) * 2003-03-14 2004-10-14 Merck & Co., Inc. Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
WO2006031676A2 (fr) * 2004-09-13 2006-03-23 Merck & Co., Inc. Antagoniste des recepteurs cgrp spirohydantoin anilide tricyclique
WO2007016087A2 (fr) * 2005-07-29 2007-02-08 Merck & Co., Inc. Antagonistes des récepteurs de cgrp de benzodiazépine hétérocyclique
WO2008073251A1 (fr) * 2006-12-08 2008-06-19 Merck & Co., Inc. Composés spirocycliques contraints servant d'antagonistes des récepteurs du cgrp
WO2008100456A2 (fr) * 2007-02-13 2008-08-21 Schering Corporation Agonistes des récepteurs adrénergiques alpha2c fonctionnellement sélectifs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MILLAN, MARK J. ET AL: "S18616, a highly potent, spiroimidazoline agonist at .alpha.2- adrenoceptors : I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS , 295(3), 1192-1205 CODEN: JPETAB; ISSN: 0022-3565, 2000, XP002559983 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057973A1 (fr) * 2009-11-11 2011-05-19 F. Hoffmann-La Roche Ag Dérivés d'oxazoline pour le traitement de troubles du système nerveux central (cns)
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
WO2012168162A1 (fr) 2011-06-06 2012-12-13 F. Hoffmann-La Roche Ag Acide acétique de benzocylcoheptène
US10961221B2 (en) 2013-12-19 2021-03-30 Bayer Pharma Aktiengesellschaft Substituted piperidinyl tetrahydroquinolines
US10472337B2 (en) 2015-02-02 2019-11-12 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10494352B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10214500B2 (en) 2015-02-02 2019-02-26 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10214501B2 (en) 2015-02-02 2019-02-26 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10239845B2 (en) 2015-02-02 2019-03-26 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10377726B2 (en) 2015-02-02 2019-08-13 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10407418B2 (en) 2015-02-02 2019-09-10 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10414738B2 (en) 2015-02-02 2019-09-17 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10421732B2 (en) 2015-02-02 2019-09-24 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10421731B2 (en) 2015-02-02 2019-09-24 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10428031B2 (en) 2015-02-02 2019-10-01 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10442776B2 (en) 2015-02-02 2019-10-15 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10450284B2 (en) 2015-02-02 2019-10-22 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10450283B2 (en) 2015-02-02 2019-10-22 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10457652B2 (en) 2015-02-02 2019-10-29 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10464910B2 (en) 2015-02-02 2019-11-05 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10494354B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US12304904B2 (en) 2015-02-02 2025-05-20 Valo Health, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10479772B2 (en) 2015-02-02 2019-11-19 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10112915B2 (en) 2015-02-02 2018-10-30 Forma Therapeutics, Inc. 3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10494353B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10464909B2 (en) 2015-02-02 2019-11-05 Forma Therapeutics, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10494351B2 (en) 2015-02-02 2019-12-03 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10501424B2 (en) 2015-02-02 2019-12-10 Forma Therapeutics, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10513501B2 (en) 2015-02-02 2019-12-24 Forma Therapeutics, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US12264137B2 (en) 2015-02-02 2025-04-01 Valo Health, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10822316B2 (en) 2015-02-02 2020-11-03 Valo Early Discovery, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10829461B2 (en) 2015-02-02 2020-11-10 Valo Early Discovery, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10829462B2 (en) 2015-02-02 2020-11-10 Valo Early Discovery, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US10870645B2 (en) 2015-02-02 2020-12-22 Valo Early Discovery, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US11891365B2 (en) 2015-02-02 2024-02-06 Valo Health, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11702412B2 (en) 2015-02-02 2023-07-18 Valo Health, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10988450B2 (en) 2015-02-02 2021-04-27 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11274084B2 (en) 2015-02-02 2022-03-15 Valo Health, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11274085B2 (en) 2015-02-02 2022-03-15 Valo Health, Inc. 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US11279681B2 (en) 2015-02-02 2022-03-22 Valo Health, Inc. 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
US9630922B2 (en) 2015-04-17 2017-04-25 Forma Therapeutics, Inc. 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
US9637453B2 (en) 2015-04-17 2017-05-02 Forma Therapeutics, Inc. 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors
US11730721B2 (en) 2016-06-17 2023-08-22 Valo Health, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10874649B2 (en) 2016-06-17 2020-12-29 Valo Early Discovery, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US12213969B2 (en) 2016-06-17 2025-02-04 Valo Health, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors

Also Published As

Publication number Publication date
AR073630A1 (es) 2010-11-17
TW201026672A (en) 2010-07-16

Similar Documents

Publication Publication Date Title
US8003624B2 (en) Functionally selective ALPHA2C adrenoreceptor agonists
EP1945626B1 (fr) Derives de l'imidazole utilises comme agonistes des recepteurs adrenergiques alpha-2c fonctionnellement selectifs
US8501747B2 (en) Functionally selective alpha2C adrenoreceptor agonists
US20120028940A1 (en) Functionally selective azanitrile alpha-2c adrenoreceptor agonists
EP1934203A2 (fr) Agonistes d'alpha 2c adrenorecepteur
EP2194986A1 (fr) Dérivés de 3,4-dihydro-1,4-benzoxazine, 3-4-dihydro-1,4-benzothiazine et 1,2,3,4-tétrahydro-quinoxaline comme agonistes des récepteurs adrénergiques alpha 2c
WO2010042475A1 (fr) Analogues de spiroaminooxazoline en tant que modulateurs de récepteur adrénergique alpha2c
EP2142538B1 (fr) Dérivés et analogues de chromane en tant qu'agonistes fonctionnellement sélectifs des récepteurs adrénergiques alpha2c
US8017642B2 (en) Functionally selective ALPHA2C adrenoreceptor agonists
US8476274B2 (en) Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators
US8383818B2 (en) Functionally selective alpha2C adrenoreceptor agonists
WO2009020578A1 (fr) Agonistes des récepteurs adrénergiques alpha2c
EP2482661A1 (fr) Analogues de biaryle spiroaminooxazoline inversés en tant que modulateurs du récepteur alpha2c adrénergique
EP2323734A1 (fr) Dérivés de cyclopropylchromène en tant que modulateurs du récepteur alpha-2c

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09736756

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09736756

Country of ref document: EP

Kind code of ref document: A1